Application of Surface Plasmon Resonance Imaging Biosensors for Determination of Fibronectin, Laminin-5, and Type IV Collagen in Plasma, Urine, and Tissue of Renal Cell Carcinoma.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101204366 Publication Model: Electronic Cited Medium: Internet ISSN: 1424-8220 (Electronic) Linking ISSN: 14248220 NLM ISO Abbreviation: Sensors (Basel) Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, c2000-

Fibronectins*/blood ; Fibronectins*/urine ; Collagen Type IV*/blood ; Collagen Type IV*/urine ; Carcinoma, Renal Cell*/urine ; Carcinoma, Renal Cell*/diagnostic imaging ; Carcinoma, Renal Cell*/blood ; Carcinoma, Renal Cell*/pathology ; Surface Plasmon Resonance*/methods ; Biosensing Techniques*/methods ; Kidney Neoplasms*/urine ; Kidney Neoplasms*/blood ; Kidney Neoplasms*/diagnostic imaging ; Kidney Neoplasms*/pathology; Humans ; Male ; Middle Aged ; Female ; Aged ; Kalinin ; Cell Adhesion Molecules/urine ; Cell Adhesion Molecules/blood ; Biomarkers, Tumor/urine ; Biomarkers, Tumor/blood ; ROC Curve

Laminin, fibronectin, and collagen IV are pivotal extracellular matrix (ECM) components. The ECM environment governs the fundamental properties of tumors, including proliferation, vascularization, and invasion. Given the critical role of cell-matrix adhesion in malignant tumor progression, we hypothesize that the concentrations of these proteins may be altered in the plasma of patients with clear cell renal cell carcinoma (ccRCC). This study aimed to evaluate the serum, urine, and tissue levels of laminin-5, collagen IV, and fibronectin among a control group and ccRCC patients, with the latter divided into stages T1-T2 and T3-T4 according to the TNM classification. We included 60 patients with histopathologically confirmed ccRCC and 26 patients diagnosed with chronic cystitis or benign prostatic hyperplasia (BPH). Collagen IV, laminin-5, and fibronectin were detected using Surface Plasmon Resonance Imaging biosensors. Significant differences were observed between the control group and ccRCC patients, as well as between the T1-T2 and T3-T4 subgroups. Levels were generally higher in plasma and tissue for fibronectin and collagen IV in ccRCC patients and lower for laminin. The ROC (Receiver operating characteristic) analysis yielded satisfactory results for differentiating between ccRCC patients and controls (AUC 0.84-0.93), with statistical significance for both fibronectin and laminin in plasma and urine. Analysis between the T1-T2 and T3-T4 groups revealed interesting findings for all examined substances in plasma (AUC 0.8-0.95). The results suggest a positive correlation between fibronectin and collagen levels and ccRCC staging, while laminin shows a negative correlation, implying a potential protective role. The relationship between plasma and urine concentrations of these biomarkers may be instrumental for tumor detection and staging, thereby streamlining therapeutic decision-making.

Anal Chim Acta. 2015 Aug 19;889:82-9. (PMID: 26343429)
Nature. 1980 Mar 6;284(5751):67-8. (PMID: 6243750)
J Urol. 2016 Jun;195(6):1892-902. (PMID: 26631499)
Biosens Bioelectron. 2018 Mar 15;101:206-212. (PMID: 29096357)
Sensors (Basel). 2012;12(4):3879-90. (PMID: 22666007)
Oncotarget. 2017 May 30;8(22):36099-36114. (PMID: 28415608)
Eur Urol. 2010 Oct;58(4):588-95. (PMID: 20674150)
Eur Urol. 2022 Nov;82(5):529-542. (PMID: 36100483)
Cancers (Basel). 2022 Aug 23;14(17):. (PMID: 36077607)
Anal Biochem. 2016 Dec 15;515:40-46. (PMID: 27717853)
Trends Cancer. 2018 Jul;4(7):472-484. (PMID: 29937046)
World J Surg Oncol. 2013 Jan 03;11:1. (PMID: 23281640)
Mol Clin Oncol. 2016 Jul;5(1):195-200. (PMID: 27330797)
Cancers (Basel). 2021 Nov 23;13(23):. (PMID: 34884982)
Sci Rep. 2014 May 30;4:5129. (PMID: 24875139)
J Pharm Biomed Anal. 2023 Jan 5;222:115103. (PMID: 36272276)
Sci Rep. 2024 Feb 16;14(1):3893. (PMID: 38365923)
Malays J Med Sci. 2014 Jan;21(1):29-36. (PMID: 24639609)
Cancer Biomark. 2011-2012;10(3-4):175-83. (PMID: 22674303)
J Gynecol Oncol. 2020 Mar;31(2):e11. (PMID: 31912669)
Int J Mol Sci. 2019 Jun 07;20(11):. (PMID: 31181623)
Semin Diagn Pathol. 2015 Mar;32(2):90-102. (PMID: 25753529)
Onco Targets Ther. 2016 Jul 07;9:4151-62. (PMID: 27462170)
BMC Cancer. 2010 Sep 22;10:503. (PMID: 20860816)
J Colloid Interface Sci. 2010 Jan 1;341(1):136-42. (PMID: 19818963)
Urologe A. 2008 Sep;47(9):1137-40. (PMID: 18651122)
Clin Cancer Res. 2008 Aug 1;14(15):4726-34. (PMID: 18676741)
Epilepsy Behav. 2015 Jul;48:66-9. (PMID: 26057352)
Oncologist. 2024 Feb 2;29(2):91-98. (PMID: 38048064)
FEBS Open Bio. 2021 Nov;11(11):2977-2987. (PMID: 34431237)
Cancer. 2017 Jan 1;123(2):200-209. (PMID: 27861752)
Anal Bioanal Chem. 2009 Feb;393(4):1157-63. (PMID: 18958451)
Micromachines (Basel). 2022 Oct 12;13(10):. (PMID: 36296077)
J Pharm Biomed Anal. 2018 Feb 20;150:1-8. (PMID: 29202303)
Acta Neurochir (Wien). 2013 Jan;155(1):165-71. (PMID: 23053286)
Anal Bioanal Chem. 2016 Jul;408(19):5269-76. (PMID: 27209594)
Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9. (PMID: 8855223)
Front Mol Biosci. 2022 Sep 16;9:988777. (PMID: 36188228)
Int J Cancer. 2001 Dec 15;94(6):763-7. (PMID: 11745475)
World J Surg Oncol. 2018 Mar 21;16(1):61. (PMID: 29562940)
Cancer Cell. 2005 Sep;8(3):241-54. (PMID: 16169468)
Cancer Lett. 2000 Jul 31;155(2):199-205. (PMID: 10822136)
Br J Cancer. 2008 Jul 8;99(1):68-71. (PMID: 18560403)
Oncol Lett. 2018 Aug;16(2):2039-2045. (PMID: 30008898)
Cell Mol Bioeng. 2016;9:1-11. (PMID: 26900407)
Biomark Res. 2017 Oct 13;5:29. (PMID: 29046806)
Biomed Rep. 2016 Apr;4(4):485-488. (PMID: 27073638)

BST-162. Polish Ministry of Education and Science grant number

Keywords: antibody-antigen interaction; biosensor SPRi; collagen type IV; fibronectin; laminin-5; renal cell carcinoma

0 (Fibronectins)
0 (Collagen Type IV)
0 (Kalinin)
0 (Cell Adhesion Molecules)
0 (Biomarkers, Tumor)

Date Created: 20241016 Date Completed: 20241016 Latest Revision: 20241019

20241019

PMC11478812

10.3390/s24196371

39409411